Indian Stock Market: Leading Picks to Consider for Investment on July 11, 2024
TVS Motor Company Ltd
Rs.2,487.00/-
TVS Launches 2024 Apache RTR 160 Racing Edition
TVS Motor Company has introduced the 2024 Apache RTR 160 Racing Edition in India.
The motorcycle, equipped with advanced technologies and performance upgrades, is priced at Rs 1.28 lakh ex-showroom.
TVS Motor is also showing interest in developing a CNG bike following the launch of Bajaj Freedom 125.
Over the past three years, TVS Motor has delivered a remarkable 305.93% return.
Ambuja Cements Ltd
Rs.674.65/-
Nomura Upgrades Ambuja Cements to ‘Buy’
Nomura has upgraded Ambuja Cements to ‘Buy’ with a target price of Rs 780, indicating an upside potential of 17-18%.
Ambuja is set to add 24 metric tonnes of capacity by FY 2025-26 through both organic and inorganic expansions.
The acquisition of Penna Cement for Rs 10,422 crore positions Ambuja as the third-largest player in South India, offering brownfield expansion opportunities.
Over the past year, Ambuja Cements has delivered a 61.54% return.
Hindustan Petroleum Corp Ltd
Rs.344.00/-
Russia-India Energy Cooperation Boosts HPCL
Hindustan Petroleum Corporation Ltd (HPCL) is set to benefit from the Russia-India joint statement on energy cooperation.
Indian refiners have saved at least $10.5 billion in foreign exchange by increasing purchases of discounted Russian crude oil.
This cooperation is expected to drive future revenue growth and cost savings for HPCL.
Over the past year, HPCL has delivered a 66.48% return.
Garden Reach Shipbuilders & Enginers Ltd
Rs.2,587.95/-
GRSE Launches GAINS 2024 to Foster Innovation
Garden Reach Shipbuilders & Engineers Ltd (GRSE) has launched the GAINS 2024 scheme to promote technological advancements through startups.
Aligned with the Make in India and Start-up India initiatives, GAINS 2024 encourages MSMEs and startups to innovate and develop solutions enhancing technological capabilities.
The scheme aims to leverage India’s strong MSME and startup ecosystem to address current and emerging challenges, fostering self-reliance in the defense sector.
Over the past five years, GRSE has delivered an impressive 2077.13% return.
Glenmark Pharmaceuticals Ltd
Rs.1,361.95/-
Glenmark Promoters to Divest 7.85% Stake in Glenmark Life Sciences
Glenmark Pharma promoters plan to divest up to 7.85% stake in Glenmark Life Sciences through an Offer for Sale (OFS).
The sale will include up to 96,09,571 equity shares at a minimum price of Rs 810 per share.
This move aims to meet the minimum public shareholding requirements and could potentially enhance stock liquidity.
Over the past year, Glenmark Life Sciences has delivered a 52.63% return.
BSE Ltd
Rs.2,319.85/-
SEBI Proposal Could Boost BSE
BSE Ltd stands to benefit if SEBI’s proposal to limit weekly expiry to one option contract per exchange is implemented.
NSE, which has two highly active contracts, could lose business, while BSE has only one upcoming contract via the Sensex.
This regulatory change could increase trading activity and market share for BSE.
Over the past year, BSE has delivered an impressive 235.86% return.
Diamond Power Infrastructure Ltd
Rs.1,314.00/-
Diamond Power Infra Secures Rs. 899.75 Crore Order from Adani
Diamond Power Infrastructure has received an order worth Rs. 899.75 crore from Adani Energy Solutions.
The company reported a 124% revenue increase and transitioned from a loss to a profit in the March quarter.
Shares are locked at a 2% upper circuit, delivering a multi-bagger return of 590% in just six months.
Over the past three years, Diamond Power Infra has achieved an astonishing 64,882.05% return.
Rajesh Exports Ltd
Rs.320.40/-
Rajesh Exports Surges on Heavy Trading Volumes
Rajesh Exports Ltd saw a significant volume surge, trading at 16.09 times the average daily volume.
Shares soared 15.1% amid heavy volumes and large-value trades.
The company appears undervalued, with a fair value estimate of Rs 507.36, indicating substantial underpricing.
Despite recent performance, Rajesh Exports has delivered a -58.71% return over the past five years.
Zydus Wellness Ltd
Rs.2,135.65/-
Zydus Wellness Gains USFDA Approval for Heart Failure Drug
Zydus Lifesciences has received final approval from the USFDA to market Sacubitril and Valsartan Tablets for chronic heart failure treatment.
The drug will be manufactured in Ahmedabad, India.
This approval is expected to enhance Zydus’ revenue growth potential in the US market.
Over the past year, Zydus Wellness has delivered a 43.38% return.
Shalby Ltd
Rs.295.30/-
Shalby Secures 30-Year Lease for New Healthcare Facility
Shalby Ltd has secured a 30-year lease on Asha Parekh Hospital in Santacruz, Mumbai, to construct a new healthcare facility.
The company anticipates its implant business will achieve positive EBITDA this year, generating revenue between Rs 130-150 crore in 2024-25 with margins of around 8-10%.
Over the past year, Shalby has delivered a 65.7% return.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of News Lounge 24×7. We advise investors to check with certified experts before taking any investment decisions.